OncRef

Clinical Trial: NCT06711900

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Information Provided By:Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Last Update Posted:2026-07-08

Study Overview

Brief Summary

The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.

Official Title

A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: SKB264
  • Drug: Pembrolizumab
  • Drug: pemetrexed
  • Drug: carboplatin or cisplatin

Other Study ID Numbers

  • SKB264-Ⅲ-14

Start Date (Actual)

2024-10-30

Primary Completion Date (Estimated)

2026-12

Study Completion Date (Estimated)

2028-12

Enrollment (Estimated)

432

Study Type

Interventional

Phase

Phase 3